Cambridge, Massachusetts-based oncology specialist Leap Therapeutics (Nasdaq: LPTX) has bought the privately-owned company Flame Biosciences.
Leap, which is focused on developing targeted and immuno-oncology therapeutics, will merge with Flame to create a new company which will continue to trade under the LPTX ticker symbol.
The new company will boast pipeline assets including FL-301, a clinical stage anti-Claudin18.2 antibody, FL-302, a pre-clinical anti-Claudin18.2/CD137 bispecific antibody and FL-501, a pre-clinical anti-GDF15 antibody.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze